Compare Cardinal Health Inc (CAH) vs Under Armour Inc Class A (UA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cardinal Health Inc vs Under Armour Inc Class A — how do they compare? Cardinal Health Inc trades at $228.03 (market cap $53.89B), while Under Armour Inc Class A trades at $6.66 (market cap $2.79B). The key difference: Cardinal Health Inc is far larger — about 19.3× Under Armour Inc Class A's market cap, and Cardinal Health Inc pays a 0.89% dividend while Under Armour Inc Class A pays none. Which is the better fit depends on your goals.
| CAH | UA | |
|---|---|---|
Market Cap | $53.89B | $2.79B |
Sector | Health | Consumer Cyclical |
52-Week High | $239.71 | $7.88 |
52-Week Low | $146.04 | $3.96 |
Enterprise Value | $58.87B | $4.42B |
Dividend Yield | 0.89% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Cardinal Health (CAH) trades at $233.66, down 0.91% in the last session, with a bullish technical signal from moving averages and strong analyst support. The company has consistently beaten earnings estimates in recent quarters, with Q1 2026 EPS of $3.17 surpassing expectations. Revenue reached $222.58 billion in 2025, though net margins remain thin at 0.62%. Recent news highlights growth potential in medical supplies, with earnings results for fiscal 2026 due August 11.
The outlook for CAH is positive, driven by earnings momentum and sector tailwinds, but risks include high leverage with debt-to-asset ratio at 16.09% and competitive pressures. Analyst consensus is bullish with a $248 price target, suggesting 6% upside. Investors should weigh solid operational cash flow against negative shareholder equity and investing outflows.
Under Armour (UA) trades at $6.61 with a neutral daily performance. The stock shows bullish technical signals from moving averages but faces fundamental challenges with negative net income margins (-9.98%) and declining revenue projections for 2026. Recent earnings showed mixed results with a Q1 2026 miss, while analyst sentiment remains divided with 40.3% buy ratings. The company's cash flow trends show significant outflows, with net cash flow negative $361.87 million in 2025.
The outlook remains cautious due to ongoing revenue declines and profitability challenges, though technical strength and institutional buying by investors like Prem Watsa provide some support. Key risks include sustained negative earnings, competitive pressures, and execution of the company's turnaround strategy. The stock presents a speculative opportunity for investors believing in management's premium product focus and inventory discipline.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Cardinal Health Inc
Cardinal Health is a leading pharmaceutical wholesaler, engaged in the sourcing and distribution of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail-order), hospitals networks, and healthcare providers. Along with AmerisourceBergen and McKesson, the three compose well over 90% of the U.S. pharmaceutical wholesale industry. Cardinal Health also supplies medical-surgical products and equipment to healthcare facilities in North America, Europe, and Asia.
Read more on CAH →About Under Armour Inc Class A
Under Armour is a leading inventor, marketer, and distributor of branded athletic performance apparel, footwear, and accessories. Built on the 'technical' performance of synthetic fabrics, the company is currently undergoing a multi-year brand evolution centered on premium product innovation, operational rigor, and a renewed focus on its North American core under the guidance of founder Kevin Plank.
Read more on UA →
